Neumora Therapeutics, Inc. (NMRA) Monday said its Phase 1 study of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The decision was followed by recently available pre-clinical data showing convulsions in rabbits.
Subsequently, the company paused its Phase 1 study, in which about 30 participants were dosed with NMRA-266. No evidence of convulsions was observed in any participant.
The company's shares were down more than 14 percent in pre-market on Monday to $10.20. The stock had closed at $13.56, down 3.21 percent on Friday. It has been trading in the range of $9.35 - $21.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.